Anzeige
Mehr »
Login
Sonntag, 26.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JNKY | ISIN: US1468756044 | Ticker-Symbol: 39CN
Frankfurt
24.01.25
08:26 Uhr
1,720 Euro
+0,010
+0,58 %
1-Jahres-Chart
CARVER BANCORP INC Chart 1 Jahr
5-Tage-Chart
CARVER BANCORP INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7201,78025.01.
1,7201,80024.01.
PR Newswire
324 Leser
Artikel bewerten:
(1)

Carver Bancorp, Inc. Definitively Rejects Dream Chasers' Offer

Finanznachrichten News

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Carver Bancorp, Inc. (Nasdaq: CARV) ("Carver" or the "Company"), the holding company for Carver Federal Savings Bank (the "Bank"), a certified Community Development Financial Institution ("CDFI") and designated Minority Depository Institution ("MDI"), announced today that its Board of Directors (the "Board") reviewed and thoroughly rejected an offer by Dream Chasers Capital Group ("Dream Chasers") to acquire 35% interest in Carver's common equity.

The Board determined that the adverse publicly disclosed regulatory history of Dream Chasers' leadership posed unacceptable reputational risks to Carver's standing and mission credibility. The Board noted the potential impact of such reputational risk on Carver's relationship with its shareholders, third-party stakeholders, regulators, and customers. Furthermore, a comprehensive review of the Dream Chasers proposal found it to be wholly deficient with respect to structural details, implied valuation, dilution, and the basic disclosure of financial and managerial resources.

In particular, the Board noted the following contributing factors in its decision to reject Dream Chasers' offer:

  1. The significant reputational risk resulting from the adverse regulatory history of Dream Chasers' leadership;
  2. The anticipated inability of Dream Chasers to obtain regulatory approval for the purchase of a material interest in Carver;
  3. The anticipated inability of Dream Chasers to qualify as a bank holding company;
  4. The lack of direct experience of Dream Chasers' leadership with a federally regulated and insured depository institution;
  5. The unsubstantiated financial resources of Dream Chasers; and
  6. The unrealistically low offer price based on Carver's intrinsic value.

As a result of its evaluation, the Board definitively determined that an association with Dream Chasers of any type is not in the best interest of Carver, its shareholders, and its community stakeholders.

About Carver Bancorp, Inc.
Carver Bancorp, Inc. (NASDAQ: CARV) is the holding company for Carver Federal Savings Bank, a federally chartered stock savings bank. Headquartered in Harlem, NY, Carver was founded in 1948 to serve African American and Caribbean-American communities in New York whose residents, businesses, and institutions had limited access to mainstream financial services. The U.S. Treasury Department has designated Carver as a Community Development Financial Institution ("CDFI") because of its community-focused banking services and dedication to its local community's economic viability and revitalization. Carver is one of the largest African- and Caribbean-American managed banks in the United States . The Bank recently expanded its online presence to include consumer checking and savings accounts across nine states, from Massachusetts to Virginia, and Washington, DC . For further information, please visit the Company's website at www.carverbank.com. Be sure to connect with Carver on Facebook, LinkedIn, and Twitter.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, risks, and uncertainties. More information about these factors, risks, and uncertainties is contained in our filings with the Securities and Exchange Commission.

Media:
Michael Herley for Carver
203.308.1409
[email protected]

Investors:
[email protected]

SOURCE Carver Bancorp, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.